- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Baby Powder Case: Johnson and Johnson directed to pay over Rs 889 crore for damages in NY
Justice Gerald Lebovits of the state supreme court in Manhattan reduced the payout from the USD 325 million that a jury awarded Donna Olson, 67, and Robert Olson, 65, in May 2019 following a 14 week trial.
New York: Johnson & Johnson has been ordered by a New York state judge to pay $120 million in damages to a Brooklyn woman and her husband after she blamed her cancer on asbestos exposure from using the company's baby powder.
Justice Gerald Lebovits of the state supreme court in Manhattan reduced the payout from the $325 million that a jury awarded Donna Olson, 67, and Robert Olson, 65, in May 2019 following a 14-week trial.
While upholding the jury's liability finding, Lebovits wrote on Nov. 11 that the damages were too high, and the Olsons could either accept the lowered award or have a new trial on damages.
The judge approved the lowered payout on Wednesday, court records show. It includes $15 million of compensatory damages and $105 million of punitive damages, down from an original $25 million and $300 million, respectively.
Johnson & Johnson did not immediately respond to requests for comment.
Jerome Block, a lawyer for the Olsons, said they were satisfied with the result and confident it would be upheld if appealed.
He also said Donna Olson's mesothelioma "is at an advanced stage, and we are hoping for the best."
Donna Olson had testified that she used Johnson's Baby Powder or Shower to Shower daily for more than 50 years.
Lebovits wrote that jurors could find that Johnson & Johnson was for many years "knowingly deceitful about" or "willfully blind to" potential health risks of its talc products, in part to maintain market share and profit.
The New Brunswick, New Jersey-based company is appealing to the U.S. Supreme Court a $2.12 billion damages award in Missouri to women who blamed their ovarian cancer on asbestos in its baby powder and other talc products.
Johnson & Johnson has faced intense scrutiny of its baby powder's safety following a 2018 Reuters investigative report that found it knew for decades about asbestos in its talc.
Internal company records, trial testimony, and other evidence show that from at least 1971 to the early 2000s, J&J's raw talc and finished powders sometimes tested positive for small amounts of asbestos.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story